Emerging Cell Therapies for Blood Cancers with Arcellx CMO, Chris Heery, MD

from Rx for Biotech · host Podcast Host Chris Leidli

In this podcast episode, we sit down with Christopher Heery, the Chief Medical Officer at Arcellx to learn about the company's pipeline and lead cell therapy, anitocabtagene autoleucel, or anito-cel, that is in development for multiple myeloma. Multiple myeloma, like lymphoma and leukemia are types of cancer that start in your blood cells.

Episode metadata supplied by the publisher feed · Published Sep 5, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Emerging Cell Therapies for Blood Cancers with Arcellx CMO, Chris Heery, MD

0:00 30:21

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Wild WinsDay Wild WinsDay Pump the hump with WILD WINSday 🐪💪: Your 3-minute weekly video boost for leadership, sales, marketing, and business breakthroughs to WIN the day!

Frequently Asked Questions

How long is this episode of Rx for Biotech?

This episode is 30 minutes long.

When was this Rx for Biotech episode published?

This episode was published on September 5, 2024.

Can I download this Rx for Biotech episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!